Research Report for the year 1980-2014

Scientific publications

Journal Articles:
  • Abo-Zaid G, Sauerbrei W, Riley RD: Individual participant data meta-analysis of prognostic factor studies: state of the art? Bmc Med Res Methodol, 2012 (online). (download: http://dx.doi.org/10.1186/1471-2288-12-56)
  • Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, Häcker B, Schumacher M, Schirrmacher V: Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. Journal of Clinical Oncology, 1997; 15: 1354-1366.
  • Altman DG, Lausen B, Sauerbrei W, Schumacher M: Danger of using "optimal" cutpoints in the evaluation of prognostic factors. Journal of the National Cancer Institute, 1994; 86: 829-835.
  • Altman DG, McShane LM, Sauerbrei W, Taube SE: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. Bmc Med, 2012; 10 (online): 51. : http://dx.doi.org/10.1186/1741-7015-10-51
  • Altman DG, McShane LM, Sauerbrei W, Taube SE: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. Plos Med, 2012; 9 (online): e1001216. : http://dx.doi.org/10.1371/journal.pmed.1001216
  • Antes G, Augustin N, Beyersmann J, Caputo A, Falck-Ytter Y, Gerds T, Gerlach A, Graf E, Holländer N, Ihorst G, Lang B, Meier-Hirmer C, Musio M, Olschewski M, Roßner R, Sauerbrei W, Schlingmann J, Schmoor C, Schulgen G, Schulte Mönting J, Schwarzer G, Schumacher M: Freiburger Beiträge zur Biometrie und Klinischen Epidemiologie. Informatik, Biometrie und Epidemiologie in Medizin und Biologie, 2004; 35: 74-122.
  • Augustin N, Sauerbrei W, Schumacher M: The practical utility of incorporating model selection uncertainty into prognostic models for survival data. Statistical Modelling, 2005; 5: 95-118.
  • Becher H, Lorenz E, Royston P, Sauerbrei W: Analysing covariates with spike at zero: a modified FP procedure and conceptual issues. Biometrical J, 2012; 54 (5): 686-700. : http://dx.doi.org/10.1002/bimj.201100263
  • Binder H, Sauerbrei W: Increasing the usefulness of additive spline models by knot removal. Comput Stat Data An, 2008; 52: 5305-5318. : http://dx.doi.org/10.1016/j.csda.2008.05.009
  • Binder H, Sauerbrei W: Stability analysis of an additive spline model for respiratory health data by using knot removal. J R Stat Soc C-appl, 2009; 58: 577-600. : http://dx.doi.org/10.1111/j.1467-9876.2009.00668.x
  • Binder H, Sauerbrei W: Adding local components to global functions for continuous covariates in multivariable regression modeling. Stat Med, 2010; 29: 800-817. : http://dx.doi.org/10.1002/sim.3739
  • Binder H, Sauerbrei W, Royston P: Comparison between splines and fractional polynomials for multivariable model building with continuous covariates: a simulation study with continuous response. Stat Med, 2013; 32: 2262-2277. : http://dx.doi.org/10.1002/sim.5639
  • Birmelin G, Zimmer V, Sauerbrei W, Pfleiderer A, Bauknecht T: Relationship between epidermal growth factor receptor (EGF-R) and various prognostic factors in human endometrial carcinoma. International Journal of Gynaecological Cancer, 1992; 2: 22-74.
  • Blettner M, Sauerbrei W: Influence of model-building strategies on the results of a case- control study. Stat Med, 1993; 12: 1325-1338.
  • Blettner M, Sauerbrei W: Metaanalysen epidemiologischer Studien Medizinische Klinik, 1998; 93: 442-445.
  • Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C: Vergleich von traditionellen Reviews, Metaanalysen und gepoolten Analysen zur Bewertung von Risikofaktoren. Informatik, Biometrie und Epidemiologie in Medizin und Biologie, 1997; 28: 148-166.
  • Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C: Traditional reviews, meta-analyses and pooled analyses in epidemiology. International Journal of Epidemiology, 1999; 28: 1-9.
  • Blettner M, Schlehofer B, Sauerbrei W: Grenzen von Metaanalysen aus publizierten Daten bei epidemiologischen Fragestellungen. Sozial- und Präventivmedizin, 1997; 42: 95-104.
  • Bojar H, Bastert G, Huebner K, Schumacher M, Schmoor C, Sauerbrei W: Prognostic Factors for node negative breast cancer patients. J Cancer Res Clin, 1990; 116: 42.
  • Boulesteix A-L, Guillemot V, Sauerbrei W: Use of pretransformation to cope with extreme values in important candidate features. Biometrical J, 2011; 53: 673-688. : http://dx.doi.org/10.1002/bimj.201000189
  • Boulesteix A-L, Sauerbrei W: Added predictive value of high-throughputmolecular data to clinical data and its validation. Brief Bioinform, 2011; 12: 215-229. : http://dx.doi.org/10.1093/bib/bbq085
  • Buchholz A, Holländer N, Sauerbrei W: On properties of predictors derived with a two-step bootstrap model averaging approach—A simulation study in the linear regression model. Comput Stat Data An, 2008; 52: 2778-2793.
  • Buchholz A, Sauerbrei W: Comparison of procedures to assess non-linear and time-varying effects in multivariable models for survival data. Biometrical J, 2011; 53: 308-331. : http://dx.doi.org/10.1002/bimj.201000159
  • Buchholz A, Sauerbrei W, Royston P: A measure for assessing functions of time-varying effects in survival analysis. Open Journal of Statistics, 2014; 4: 977-998. : http://dx.doi.org/10.4236/ojs.2014.411092
  • Colleoni M, Litman HJ, Castiglione-Gertsch M, Sauerbrei W, Gelber RD, Bonetti M, Coates AS, Schumacher M, Bastert G, Rudenstam C-M, Schmoor C, Lindtner J, Collins J, Thürlimann B, Holmberg SB, Crivellari D, Beyerle C, Neumann RLA, Goldhirsch A for the International Breast Cancer Study Group, the German Breast Cancer Study Group: Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Brit J Cancer, 2002; 86 (11): 1705-1714.
  • De Bin R, Sauerbrei W, Boulesteix A-L: Investigating the prediction ability of survival models based on both clinical and omics data: two case studies. Stat Med, 2014; 33: 5310-5329. : http://dx.doi.org/10.1002/sim.6246
  • de Haes H, Olschewski M, Kaufmann M, Schumacher M, Jonat W, Sauerbrei W: Quality of life in Goserelin-treated versus Cyclophosphamide + Methotrexate + Fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: The Zoladex Early Breast Cancer Research Association Trialists Group. J Clin Oncol, 2003; 21: 4510-4516.
  • Diepgen TL, Sauerbrei W, Fartasch M: Development and validation of diagnostic scores for atopic dermatitis incorporating criteria of data quality and practice Journal of Clinical Oncology, 1996; 9: 1031-1038.
  • Diepgen T L, Fartasch M, Sauerbrei W: Analyse diagnostischer Kriterien, mit Hilfe multifaktorieller statistischer Methoden am Beispiel der Atopie. Zentralblatt Haut- und Geschlechtskrankheiten, 1990; 158: 404.
  • Edler, L, Olschewski, M, Sauerbrei, W: Der Therapieoptimierungsvergleich (TOPV): Keine geeignete Alternative zur randomisierten Studie (RCT) Forum DKG, 1996; 11: 391-393.
  • Fehm T, Sauerbrei W: Information from CTC measurements for metastatic breast cancer prognosis—we should do more than selecting an “optimal cut point”. Breast Cancer Res Tr, 2010; 122: 219-220. : http://dx.doi.org/10.1007/s10549-010-0762-x
  • Fogelman I, Blake GM, Palmer M, Sauerbrei W, Schumacher M, Serin D, Stewart A, Wilpshaar W: Bone mineral density in premenopasual women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporosis Int, 2003; 14: 1001-1006.
  • Frobenius W, v. Maillot K, Sauerbrei W, Lang N: Bei Peritonitis nach Sektio - Champagner löffelweise - Aus der Geschichte der Geburtshilfe in Erlangen - Daten von rund 60000 Entbindungen in 100 Jahren Gynäkologisch-geburtshilfliche Rundschau, 1996; 36: 212-220.
  • Graf E, Schmoor C, Sauerbrei W, Schumacher M: Assessment and comparison of prognostic classification schemes for survival data. Statistics in Medicine, 1999; 18: 2529-2545.
  • Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, Briggs A, Udumyan R, Moons KG, Steyerberg EW, Roberts I, Schroter S, Altman DG, Riley RD, PROGRESS Group (Sauerbrei W): Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. Brit Med J, 2013; 346 (online): e5595. : http://dx.doi.org/10.1136/bmj.e5595
  • Hingorani AD, van der Windt DA, Riley RD, Abrams K, Moons KGM, Steyerberg EW, Schroter S, Sauerbrei W, Altman DG, Hemingway H, for the PROGRESS Group: Prognosis research strategy (PROGRESS) 4: Stratified medicine research. Brit Med J, 2013; 346 (online): e5793. : http://dx.doi.org/10.1136/bmj.e5793
  • Hohls M, Sauerbrei W, Hasse J, Stoelben E: Postoperative Sterblichkeit beim Bronchialkarzinom in Abhängigkeit vom Tumorstadium. Z Herz- Thorax- Gefäßchir, 2002; 16: 1-7.
  • Holländer N, Augustin N, Sauerbrei W: Investigation on the improvement of prediction by bootstrap model averaging. Method Inform Med, 2006; 45: 44-50.
  • Holländer N, Sauerbrei W, Schumacher M: Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint. Stat Med, 2004; 23: 1701-1713.
  • Ikenberg H, Sauerbrei W, Schottmüller U, Spitz, C, Pfleiderer A: HPV DNA in cervical carcinoma - correlation with clinical data and influence on prognosis. International Journal of Cancer, 1994; 59: 322-326.
  • Jäger W, Sauerbrei W: Effect of timing of surgery during the menstrual cycle of premenopausal breast cancer patients. Breast Cancer Research and Treatment, 1995; 34: 279-287.
  • Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B: Goserelin versus Cyclophosphamide, Methotrexate, and Fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol, 2002; 20 (24): 4628-4635.
  • Kasenda B, Sauerbrei W, Royston P, Briel M: Investigation of continuous effect modifiers in a meta-analysis on higher versus lower PEEP in patients requiring mechanical ventilation - protocol of the ICEM study. Systematic Reviews, 2014; 3 (online): 46. : http://dx.doi.org/10.1186/2046-4053-3-46
  • Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M, Sauerbrei W on behalf of the Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group: Survival analyses from the ZEBRA study: goserelin (Zoladex TM) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer, 2003; 39: 1711-1717.
  • Kieback DG, Fischer D-C, Engehausen DG, Sauerbrei W, Oehler MK, Tong X-W, Aguilar-Cordova E: Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer. Cancer Gene Ther, 2002; 9: 478-481.
  • Kleine W, Giese E, Behre J, Sauerbrei W: Recurrence of breast cancer. Journal of Cancer Research and Clinical Oncology, 1992; 118: R113.
  • Kommoss F, Pfisterer J, Geyer H, Thome M, Sauerbrei W, Pfleiderer A: Estrogen and progesteron receptors in ovarian neoplasms: discrepant results of immunohistochemical and biochemical methods. Int J Gynecol Cancer, 1991; 1: 147-153.
  • Kommoss F, Pfisterer J, Idris T, Giese E, Sauerbrei W, Schäfer W, Thome M., Pfleiderer A.: Steroid receptors in carcinoma of the breast: Results of immunocytochemical and biochemical determination and their effects upon stort-term prognosis. Analytical and Quantitative Cytology and Histology, 1994; 16: 203-210.
  • Kommoss F, Pfisterer J, Thome M, Schäfer W, Sauerbrei W, Pfleiderer A: Steroid receptors in ovarian carcinoma: Immunohistochemical determination may lead to new aspects. Gynecologic Oncology, 1992; 47: 317-322.
  • Kommoss F, Wölfle J, Bauknecht T, Pfisterer J, Kiechle-Schwarz M, Pfleiderer A, Sauerbrei W., Kiehl R., Kacinski B.M.: Co-epression of M-CSF transcript and protein, FMS (M-CSF receptor) transcripts and protein, and steroid receptor content in adencocarcinomas of the ovary. Journal of Pathology, 1994; 174: 111-119.
  • Lutterbach J, Sauerbrei W, Guttenberger R: Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol, 2003; 179: 8-15.
  • Madjar H, Ladner HA, Sauerbrei W, Schwoerer D, Kleine W: Preoperative staging of breast cancer by palpation, mammography and computed sonography. Ultrasound Obst Gyn, 1993; 3: 185-190.
  • Madjar H, Muench S, Sauerbrei W, Bauer H, Schillinger H: Differenzierte Mammadiagnostik durch CW-Doppler-Ultraschall. Radiologie, 1990; 30: 193-197.
  • Madjar H, Prömpeler HJ, Sauerbrei W, Mundinger A, Pfleiderer A: Differential diagnosis of breast lesions by color Doppler. Ultrasound Obstetrics Gynecology, 1995; 6: 199-203.
  • Madjar H, Prömpeler W, Sauerbrei W, Wolfarth R, Pfleiderer A: Color doppler flow critieria of breast lesions. Ultrasound in Medicine & Biology, 1994; 20: 849-858.
  • Madjar H, Sauerbrei W, Hansen L: Multivariate Analysis of Flow Data in Breast Lesions and Validation in a Normal Clinical Setting. Multivariate Analyse von Flussdaten bei Mammatumoren und Validierung unter normalen klinischen Routinebedingungen. Ultraschall Med, 2011; 32: 511-517. : http://dx.doi.org/10.1055/s-0029-1245800
  • Madjar H, Sauerbrei W, Muench S, Proempeler H, Schillinger H: Methodenanalyse zur Doppleruntersuchung der weiblichen Brust. Ultraschall in Medizin, 1990; 11: 196-201.
  • Madjar H, Sauerbrei W, Muench S, Schillinger H: Continuous-wave and pulsed doppler studies of the breast: clinical results and effect of transducer frequency. Ultrasound in Medicine & Biology, 1991; 17: 31-39.
  • Madjar H, Sauerbrei W, Prömpeler HJ, Wolfarth R, Gufler H: Color Doppler and duplex flow analysis for classification of breast lesions Gynecologic Oncology, 1997; 64: 392-403.
  • Madjar H, Sauerbrei W, Rachowska A, Pfleiderer H: Vergleich von hochauflösender Sonographie und Mammographie. Ultraschall Klinische Praxis, 1991; 6: 290-297.
  • Madjar H, Sauerbrei W, Wolfarth R, Prömpeler H, Bauknecht T, Pfleiderer A: Color doppler imaging and duplex measurements for determination of abnormal breast vascularity. 8th International congress on the ultrasonic examination of the breast, Heidelberg 1.-4.7.1993. Bildgebung - Imaging, 1993; 60: 17.
  • Mallett S, Timmer A, Sauerbrei W, Altman DG: Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Brit J Cancer, 2010; 102: 173-180. : http://dx.doi.org/10.1038/sj.bjc.6605462
  • McShane LM, Altman DG, Sauerbrei W: Identification of clinically useful cancer prognostic factors: What are we missing? J Natl Cancer I, 2005; 97: 1023-1025.
  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer I, 2005; 97: 1180-1184.
  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol, 2005; 2: 416-422.
  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: REporting recommendations for tumor MARKer prognostic studies (REMARK). Brit J Cancer, 2005; 22: 387-391.
  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: REporting recommendations for tumor MARKer prognostic studies (REMARK). Eur J Cancer, 2005; 41: 1690-1696.
  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol, 2005; 23: 9067-9072.
  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK);Statistics Subcommittee of the NCI-EORTC working Group on Cancer Diagnostics Nat Clin Pract Urol(Nature Clinical Practise Urology), 2005; 2: 416-422.
  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, for the statistics Subcommittee of the NCI-EORTC working Group on Cancer Diagnostics: Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol, 2006; 28: 99-105.
  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Tr, 2006; 100: 229-235.
  • Meerpohl HG, Kühble H, Sauerbrei W, Achterrath W, Pfleiderer A: Cyclophosphamide/Cisplatin (CTX/PT) vs. CTX/Carboplatin (CarboPt) in advanced ovarian carcinoma: a randomized multicenter study J Cancer Res Clin, 1990; 116: 1120.
  • Meerpohl HG, Sauerbrei W, for the GOCA-group: Current results of prospective clinical trials in patients with advanced ovarian carcinoma. Journal of Cancer Research and Clinical Oncology, 1992; 118: R174.
  • Meerpohl HG, Sauerbrei W, Kühnle H, Schumacher M, Pfleiderer A for the German, Ovarian Cancer Study Group: Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease Gynecologic Oncology, 1997; 66: 75-84.
  • Meerpohl HG, Sauerbrei W, Scheulen ME, Pfleiderer A, for the GOCA-group: Advanced ovarian cancer: analysis of factors influencing resectability at initial surgery. Proceedings American Society Clinical Oncology, 1991; 10: 193.
  • Merkle E, Seidl C, Fuchs U, Sauerbrei W, Wirtz PM: Adjuvante Chemotherapie des Mammakarzinoms mit dem CMFV-Schema Geburtshilfe und Frauenheilkunde, 1990; 50: 215-219.
  • Pfisterer J, Kommoss F, Sauerbrei W, Rendl I, Kiechle M, Kleine W, Pfleiderer A: Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma. Gynecologic Oncology, 1995; 58: 149-156.
  • Pfisterer J, Kommoss F, Sauerbrei W, Renz H, du Bois A, Kiechle-Schwarz M, Pfleiderer A: Cellular DNA content and survival in advanced ovarian carcinoma. Cancer, 1994; 74: 2509-2515.
  • Pfleiderer A, Meerpohl HG, Sauerbrei W, Teufel G, Schumacher M: Are there different types of ovarian cancer? J Cancer Res Clin, 1990; 116: 1077.
  • Prömpeler H, Madjar H, Sauerbrei W, Lattermann U, Pfleiderer A: Quantitative flow parameters for classification of ovarian tumors by transvaginal color doppler sonography. Ultrasound Obstet Gynecology, 1994; 4: 406-413.
  • Prömpeler HJ, Madjar H, Sauerbrei W, Lattermann U, du Bois A, Breckwoldt M, Pfleiderer A: Transvaginale Farbdoppler Sonographie bei Ovarialtumoren. Geburtshilfe und Frauenheilkunde, 1994; 54: 216-121.
  • Prömpeler HJ, Madjar H, Sauerbrei W, Lattermann U, Pfleiderer A: Diagnostic formula for the differentiation of adnexal tumors by transvaginal sonography Obstetrics & Gynecology, 1997; 89: 428-433.
  • Randelzhofer B, Prömpeler HJ, Sauerbrei W, Madjar H, Emons G: Value of sonomorphologic criteria of endometrium in women with postmenopausal bleeding. A multivariate analysis. Ultrasound Obst Gyn, 2002; 19: 62-68.
  • Rauschecker HF, Gatzemeier W, Sauer R, Seegenschmiedt M, Schauer A, Ummenhofer L, Sauerbrei W, Schmoor C, Schumacher M: German Breast Cancer Study Group study on therapy of small breast cancer. Four-year results. Breast Cancer Res Tr, 1993; 27: 142.
  • Rauschecker HF, Gatzemeier W, Sauer R, Seegenschmiedt MH, Schauer A, Ummenhofer L, Sauerbrei W, Schmoor C, Schumacher M: Erste Ergebnisse des Projekts der Deutschen Brustkrebsstudiengruppe (GBSG) zur "Brusterhaltenden Therapie des kleinen Mammacarcinoms". Der Chirurg, 1992; 63: 495-500.
  • Rauschecker HF, Gatzemeier W, Schumacher M, Sauerbrei W, Schmoor C, Sauer R, Seegenschmidt MH, Schauer A, Ummenhofer L, Scheurlen H: Concept and first results related to the structural relationship of various prognostic factors Tumor Diagnostik und Therapie, 1990; 11: 243-248.
  • Rauschecker HF, Sauerbrei W, Gatzemeier W, Sauer R, Schauer A, Schmoor C, Schumacher M for the German, Breast Cancer Study Group: Eight-year results of a prospective non-randomised study on therapy of small breast cancer. European Journal of Cancer, 1998; 34: 315-323.
  • Rauschecker HF, Sauer R, Schauer A, Schumacher M., Olschewski M, Sauerbrei W, Seegenschmiedt MH, Schmoor C: Therapy of small breast cancer - Four-year results of a prospectiv non-randomized study. Breast Cancer Research and Treatment, 1995; 34: 1-13.
  • Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, Malats N, Briggs A, Schroter S, Altman DG, Hemingway H, PROGRESS Group (Sauerbrei W): Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. Plos Med, 2013; 10 (2) (online): e1001380. : http://dx.doi.org/10.1371/journal.pmed.1001380
  • Riley RD, Sauerbrei W, Altman DG: Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Brit J Cancer, 2009; 100: 1219-1229. : http://dx.doi.org/10.1038/sj.bjc.6604999
  • Royston P, Altman DG, Sauerbrei W: Dichotomizing coninuous predictors in multiple regression: a bad idea. Stat Med, 2006; 25: 127-141.
  • Royston P, Ambler G, Sauerbrei W: The use of fractional polynomials to model continuous risk variables in epidemiology. International Journal of Epidemiology, 1999; 28: 964-974.
  • Royston P, Sauerbrei W: Stability of multivariable fractional polynomial models with selection of variables and transformations: a bootstrap investigation. Stat Med, 2003; 22: 639-659.
  • Royston P, Sauerbrei W: A new measure of prognostic separation in survival data. Stat Med, 2004; 23: 723-748.
  • Royston P, Sauerbrei W: A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med, 2004; 23: 2509-2525.
  • Royston P, Sauerbrei W: Building multivariable regression models with continuous covariates in clinical epidemiology. Method Inform Med, 2005; 4: 561-571.
  • Royston P, Sauerbrei W: Improving the robustness of fractional polynomial models by preliminary covariate transformation: A pragmatic approach. Comput Stat Data An, 2007; 51: 4240-4253.
  • Royston P, Sauerbrei W: Multivariable modeling with cubic regression splines: A principled approach. The Stata Journal, 2007; 7: 45-70.
  • Royston P, Sauerbrei W: Bootstrap assessment of the stability of multivariable models. Stata J, 2009; 9: 547-570.
  • Royston P, Sauerbrei W: Interaction of treatment with a continuous variable: simulation study of significance level for several methods of analysis. Stat Med, 2013; 32 (22): 3788-3803. : http://dx.doi.org/10.1002/sim.5813
  • Royston P, Sauerbrei W: Interaction of treatment with a continuous variable: simulation study of power for several methods of analysis. Stat Med, 2014; 33: 4695-4708. : http://dx.doi.org/10.1002/sim.6308
  • Royston P, Sauerbrei W, Becher H: Modelling continuous exposures with a spike at zero: A new procedure based on fractional polynomials. Stat Med, 2010; 29: 1219-1227. : http://dx.doi.org/10.1002/sim.3864
  • Royston P, Sauerbrei W, Ritchie A: Is treatment with interferon-alpha effectiv in all patients with metastatic renal carcinoma? A new approach to the investigations of interactions. Brit J Cancer, 2004; 90: 794-799.
  • Sauerbrei W: Antwort auf den Kommentar von L. Edler und C. Quinteiro. Biometrie und Informatik in Medizin und Biologie, 1989; 22: 77-83.
  • Sauerbrei W: Bedeutung und Evaluierung prognostischer Faktoren Zentralblatt Haut- und Geschlechtskrankheiten, 1990; 158: 403-404.
  • Sauerbrei W: Antwort auf den Kommentar von L. Edler und C. Quinteiro. Biometrie und Informatik in Medizin und Biologie, 1991; 22: 77-83.
  • Sauerbrei W: Zur Bewertung von Therapiestudien beim Mammakarzinom. Onkologie, 1991; 14: 303-312.
  • Sauerbrei W: The use of resampling methods to simplify regression models in medical statistics. Applied Statistics, 1999; 48: 313-329.
  • Sauerbrei W, Abrahamowicz M, Altman DG, le Cessie S, Carpenter J, and on behalf of the STRATOS initiative: STRengthening Analytical Thinking for Observational Studies: the STRATOS initiative. Stat Med, 2014; 33: 5413-5432. : http://dx.doi.org/10.1002/sim.6265
  • Sauerbrei W, Bastert G, Bojar H, Beyerle C, Neumann RLA, Schmoor C, Schumacher M for the German, Breast Cancer Study Group: Randomized 2x2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: An update based on 10 years' follow-up. J Clin Oncol, 2000; 18: 94-101.
  • Sauerbrei W, Bastert G, Schmoor C: Prognostic effect of timing of surgery during menstrual cycle in pre-menopausal breast cancer patients. International Journal of Cancer, 1994; 59: 149-150.
  • Sauerbrei W, Blettner M: Interpretation der Ergebnisse von 2×2-Tafeln: Teil 9 der Serie zur Bewertung wissenschaftlicher Publikationen. Interpreting Results in 2×2 Tables: Part 9 of a Series on Evaluation of Scientific Publications. Deutsches Ärzteblatt International, 2009; 106: 795-800. : http://dx.doi.org/10.3238/arztebl.2009.0795
  • Sauerbrei W, Blettner M, Schmoor C, Bojar H, Schumacher M for the German, Breast Cancer Study Group: The effect of oral contraceptive use on the prognosis of node positive breast cancer patients. European Journal of Cancer, 1998; 34: 1348-1351.
  • Sauerbrei W, Blettner M, Schumacher M: Letters Re: Meta-analysis comparing cisplatin total dose intensity and survifal: a critical reappraisal Gynecologic Oncology, 1996; 62: 427-429.
  • Sauerbrei W, Blettner M, Schumacher M: The importance of basic statistical principles for the intepretation of epidemiological data Onkologie, 1997; 20: 455-460.
  • Sauerbrei W, Boulesteix A-L, Binder H: Stability investigations of multivariable regression models derived from low- and high-dimensional data. J Biopharm Stat, 2011; 21: 1206-1231. (download: http://dx.doi.org/10.1080/10543406.2011.629890)
  • Sauerbrei W, Graf E, Schumacher M: Randomisation und Patientenaufklärung. Notwendigkeit der Randomisation aus methodischer Sicht Onkologie, 1996; 19: 184-190.
  • Sauerbrei W, Holländer N, Buchholz A: Investigation about a screening step in model selection. Stat Comput, 2008; 18: 195-208.
  • Sauerbrei W, Holländer N, Riley RD, Altman DG: Evidence-based assessment and application of prognostic markers: the long way from single studies to meta-analysis. Commun Stat-theor M, 2006; 35: 1333-1342.
  • Sauerbrei W, Hübner K, Schmoor C, Schumacher M for the German, Breast Cancer Study Group: Validation of existing and development of new prognostic classification schemes in node negative breast cancer. Breast Cancer Research and Treatment, 1997; 42: 149-163.
  • Sauerbrei W, Jäger W: Timing of breast cancer surgery - some arguments that there is no effect. Annals of Oncology, 1994; 5: 25-27.
  • Sauerbrei W, Madjar H, Prömpeler HJ: Use of logistic regression and a classification tree approach for the development of diagnostic rules: Differentiation of benign and malignant breast tumors based on color doppler flow signals. Methods of Information in Medicine, 1998; 37: 226-234.
  • Sauerbrei W, Meier-Hirmer C, Benner A, Royston P: Multivariable regression model building by using fractional polynomials: Description of SAS, STATA and R programs. Comput Stat Data An, 2006; 50: 3464-3485.
  • Sauerbrei W, Royston P: Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials Journal of the Royal Statistical Society, Series A, 1999; 162: 71-94.
  • Sauerbrei W, Royston P: Modelling to extract more information from clinical trials data: On some roles for the bootstrap. Stat Med, 2007; 26: 4989-5001.
  • Sauerbrei W, Royston P: A new strategy for meta-analysis of continuous covariates in observational studies. Stat Med, 2011; 30 (28): 3341-3360. : http://dx.doi.org/10.1002/sim.4333
  • Sauerbrei W, Royston P, Binder H: Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med, 2007; 26: 5512-5528.
  • Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M and the German Br: Modelling the effects of standard prognostic factors in node-positive breast cancer. British Journal of Cancer, 1999; 79: 1752-1760.
  • Sauerbrei W, Royston P, Look M: A new proposal for multivariable modelling of time-varying effects in survival data based on fractional polynomial time-transformation. Biometrical J, 2007; 49: 453-473.
  • Sauerbrei W, Royston P, Zapien K: Detecting an interaction between treatment and a continuous covariate: A comparison of two approaches. Comput Stat Data An, 2007; 51: 4054-4063.
  • Sauerbrei W, Schmoor c, Schumacher M, for the GBSG: Identification of high and low risk groups in node negative breast cancer patients. Development and validation of indices. Breast Cancer Res Tr, 1993; 27: 139.
  • Sauerbrei W, Schumacher M: A bootstrap resampling procedure for model building: Application to the Cox regression model. Stat Med, 1992; 11: 2093-2109.
  • Sauerbrei W, Schumacher M: Basic statistical principles for the evaluation of risk factors. 8th International congress on the ultrasonic examination of the breast, Heidelberg, 1.-4.7.1993. Bildgebung - Imaging, 1993; 60: 5.
  • Sauerbrei W, Schumacher M: Aspekte der statistischen Evaluation neuer Prognosefaktoren: Illustration bei Studien in der Onkologie. Geburtshilfe und Frauenheilkunde, 1999; 59: 483-487.
  • Sauer R, Rauschecker HP, Gatzemeier W, Schumacher M, Sauerbrei W, Seegenschmiedt MH, Schauer A, Marx D: Therapy of small breast cancer - comparison between mastectomy and breast preserving therapy. International Journal Radiation Oncology Biol. Phys., 1991; 21 Suppl. 1: 129-130.
  • Sauer R, Schauer A, Rauschecker HF, Schumacher M, Gatzemeier W, Sauerbrei W, Dunst J, Seegenschmiedt MH, Marx D, for the German Breast Cancer Study Group:: Breast preservation versus mastectomy in early breast cancer - 1991 update of the GBSG 1 - protocol and prognostic factors. Strahlentherapie und Onkologie, 1992; 168: 191-202.
  • Schauer A, Marx D, Ummenhofer L, Rauschecker HF, Gatzemeier W, Sauer R, Schumacher M, Sauerbrei W: Die Multicenterstudie Kleines Mammakarzinom: Vorläufige Ergebnisse - Neue Aspekte. Deutsches Ärzteblatt, 1990; 87: C2125-C2130.
  • Schmoor, C, Sauerbrei, W, Schumacher, M: Sample size considerations for the evaluation of prognostic factors in survival analysis Stat Med, 2000; 19: 441-452.
  • Schmoor C, Bastert G, Dunst J, Bojar H, Christmann D, Unbehaun V, Tümmers G, Bauer W, Sauerbrei W, Schumacher M for the German Breast Cancer Study Group: Randomized trial on the effect of radiotherapy in addition to 6 cycles of CMF in node positive breast cancer patients Int J Cancer, 2000; 86: 408-415.
  • Schmoor C, Eisele C, Graf E, Sauerbrei W, Klingele B, Hellmer A, Rossner R, Schumacher M: Arbeitsweisen des Methodischen Zentrums am Institut für Medizinische Biometrie und Medizinische Informatik der Universität Freiburg bei der biometrischen Betreuung klinischer Studien Informatik, Biometrie und Epidemiologie in Medizin und Biologie, 1997; 28: 253-274.
  • Schmoor C, Olschewski M, Sauerbrei W, Schumacher M: Long-term follow-up of patients in four prospective studies of the German Breast Cancer Study Group (GBSG): A summary of key results. Onkologie, 2002; 25: 143-150.
  • Schmoor C, Sauerbrei W, Baster G, Schumacher M for the German, Breast Cancer Study Group, (GBSG): Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. Journal of Clinical Oncology, 2000; 18: 1696-1708.
  • Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M for the German Breast Cancer Study Group (GBSG): Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer, 2001; 37: 1123-1131.
  • Schulgen G, Schmoor C, Sauerbrei W, Schumacher M: A note on estimating local recurrence rates in clinical trials on the treatment of breast cancer Breast Cancer Research and Treatment, 1998; 49: 87-91.
  • Schumacher M, Bastert G, Bojar H, Hübner K, Olschewski M, Sauerbrei W, Schmoor C., Beyerle C., Neumann R.L.A., Rauschecker H.F. for the Germ, Cancer Study Group (GBSG): Randomized 2x2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. Journal of Clinical Oncology, 1994; 12: 2086-2093.
  • Schumacher M, Bastert G, Bojar H, Hübner K, Sauerbrei W, Schmoor C, Olschewski M, for the German Breast Cancer Study Group: A randomized clinical trial evaluating the duration of chemotherapy in patients with primary, node-positive breast cancer. The Breast, 1993; 2: 194.
  • Schumacher M, Holländer N, Sauerbrei W: Resampling and cross-validation techniques: A tool to reduce bias caused by model building? Statistics in Medicine, 1997; 16: 2813-2827.
  • Schumacher M, Olschewski M, Sauerbrei W: On the importance of controlled clinical trials in oncology. Journal of Cancer Research and Clinical Oncology, 1992; 118: R 159.
  • Schumacher M, Sauerbrei W, Schmoor C: Prognostische Faktoren in den GBSG-Mammakarzinomstudien I-III. Zentralblatt Radiologie, 1993; 147: 793.
  • Schumacher M, Schmoor C, Sauerbrei W, Schauer A, Umenhofer L, Gatzemeier W, Rauschecker HF: The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Tr, 1993; 25: 235-245.
  • Schumacher M, Schmoor C, Sauerbrei W, Schauer A, Umenhofer L, Gatzemeier W, Rauschecker HF, fot the German Breast Cancer Study Group (GBSG): The prognostic effect of histological tumor grade in noce-negative breast cancer patients. The Breast, 1993; 2: 205.
  • Seegenschmiedt M, Sauerbrei W, Sauer R, for the Gerrman Breast Study Group (GBSG): Schumacher M, Schauer A, Rauschecker HF, for participating institutions within the GBSG: Dinkloh H, Dühmke E, Haase KD, Haase W, Heisen E, Heinze HG, Janik I, Szepesi S: Quality control review for radiotherapy of small breast cancer: Analysis of 708 patients in the GBSG 1 trial. Stahlentherapie und Onkologie, 1993; 6: 339-350.
  • Seegenschmiedt MH, Sauer R, Sauerbrei W, Schumacher M, Gatzemeier W, Rauschecker HF: Qualitätskontrolle (QC) der perkutanen Radiotherapie (RT) beim kleinen Mammakarzinom: Ergebnisse bei 708 Patienten in der GBSG 1 Studie. Zentralblatt Radiologie, 1993; 147: 940-941.
  • Seegenschmiedt MH, Sauer R, Sauerbrei W, Schumacher M, Gatzemeier W, Rauschecker HF: Spätfolgen nach perkutaner Radiotherapie beim kleinen Mammakarzinom. Erste Ergebnisser der GBSG 1 Studie. Zentralblatt für Radiologie, 1993; 147: 941.
  • Seegenschmiedt MH, Sauer R, Schumacher M, Sauerbrei W, Rauschecker HF, Gatzemeier W: Quality control for external beam radiotherapy of small breast cancer. Radiology, 1992; 185: 295.
  • Steiner W, Stenglein C, Fietkau R, Sauerbrei W: Therapie des Hypopharynxkarzinoms IV: Langzeitergebnisse der transoralen Lasermikrochirurgie von Hypopharynxkarzinomen. HNO, 1994; 42: 147-156.
  • Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, Riley RD, Hemingway H, Altman DG, PROGRESS Group (Sauerbrei W): Prognosis Research Strategy (PROGRESS) 3: prognostic model research. Plos Med, 2013; 10 (2) (online): e1001381. : http://dx.doi.org/10.1371/journal.pmed.1001381
  • Stoelben E, Sauerbrei W: Tumor stage and early mortality for surgical resection in lung cancer. Langenbecks Arch Surg, 2003; 388: 116-121.
  • Stollhoff R, Sauerbrei W, Schumacher M: An experimental evaluation of boosting methods for classification. Method Inform Med, 2010; 3: 219-229. : http://dx.doi.org/10.3414/ME0543
  • Ulm, K, Schmoor C, Sauerbrei W, Kemmler G, Aydemir Ü, Müller B, Schumacher M: Strategien zur Auswertung einer Therapiestudie mit der Überlebenszeit als Zielkriterium. Biometrie und Informatik in Medizin und Biologie, 1989; 20: 171-205.
  • Vach K, Sauerbrei W, Schumacher M: Variable selection and shrinkage: comparison of some approaches. Stat Neerl, 2001; 55: 53-75.
  • Van Houwelingen HC, Sauerbrei W: Cross-validation, shrinkage and variable selection in linear regression revisited. Open Journal of Statistics, 2013; 3: 79-102. : http://dx.doi.org/10.4236/ojs.2013.32011
  • Watermann D, Madjar H, Sauerbrei W, Hirt V, Prömpeler H, Stickeler E: Assessment of breast cancer vascularisation by Doppler ultrasound as a prognostic factor of survival. Oncol Rep, 2004; 11: 905-910.
  • Winzer KJ, Buchholz A, Guski H, Frohberg HD, Diekmann F, Possinger K, Sauerbrei W: Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998. Onkologie, 2013; 36: 727-736. : http://dx.doi.org/10.1159/000356805
  • Winzer K-J, Sauerbrei W, Braun M, Liersch T, Dunst J, Guski H, Schumacher M, and for the German Breast Cancer Study Group (GBSG): Radiation therapy and tamoxifen after breast conserving surgery: updated results of a 2×2 randomized clinical trial in patients with low risk of recurrence. Eur J Cancer, 2010; 46: 95-101. : http://dx.doi.org/10.1016/j.ejca.2009.10.007
  • Winzer K-J, Sauer R, Sauerbrei W, Schneller E, Jaeger W, Braun M, Dunst J, Liersch T, Zedelius M, Brunnert K, Guski H, Schmoor C, Schumacher M for the German Breast Cancer Study Group (GBSG): Radiation therapy after breast-conserving surgery - first results of a randomised clinical trial in patients with low risk of recurrence. Eur J Cancer, 2004; 40: 998-1005.
Reviews:
  • Ikenberg, H, Wiegering, I, Pfisterer J, Kiechle-Schwarz M, Schmitt B, Sauerbrei W, Pfleiderer A: Human Papillomavirus DNA in tumorfree regional lymph nodes - A potential prognostic marker in cervical carcinoma Cancer Journal from Scientific American, 1996; 2: 28-34.
  • Pfisterer J, Kommoss F, Sauerbrei W, Baranski B, Kiechle M: DNA flow cytometry in stage IB and II cervical carcinoma. International Journal of Gynecological Cancer, 1996; 6: 54-60.
  • Prömpeler HJ, Madjar H, Sauerbrei W: Classification of adnexal tumors by transvaginal color Doppler. Gynecologic Oncology 5, 1996; 61: 354-363.
  • Prömpler HJ, Madjar H, Sauerbrei W, Lattermann U, Pfleiderer A: Kombinierte Beurteilung von Ovarialtumoren mit transvaginaler B-Bild- und Farbdoppler-Sonographie. Geburtshilfe und Frauenheilkunde, 1996; 56: 345-350.
Books:
  • Royston P, Sauerbrei W: Multivariable Model-buidling. A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables., Chichester: John Wiley & Sons Ltd., 1. Auflage, 2008 (Wiley Series in Porbability and Statistics).
Book Chapters:
  • Antes G, Sauerbrei W: Simulations in the statistical system SAS. In: Faulbaum F (Hrsg.): Softstat '91 Advances in Statistical Software Stuttgart: Fischer, 1992; 187-194 (3).
  • Blettner M, Sauerbrei W: Methodologische Aspekte bei der Untersuchung von Spontanremissionen von Tumoren. In: Heim, M.E. und Schwarz, R. (Hrsg.): Spontanremission in der Onkologie: theoretische Modelle und klinische Befunde; mit 20 Tabellen , 1998; 29-38.
  • Gerlach A, Holländer N, Ihorst G, Olschewski M, Sauerbrei W, Schlingmann J, Schmoor C, Schulgen G, Schwarzer G, Schumacher M: Freiburg contributions to biometry and clinical epidemiology. In: Joachim Kunert und Götz Trenkler (Hrsg.): Mathematical Statistics with Applications in Biometry, 1. Auflage. Lohmar Köln: Josef Eul Verlag, 2001; 49-70.
  • Graf E, Sauerbrei W, Schumacher M, Schmoor C: Berücksichtigung prognostischer Faktoren bei der Planung von Therapiestudien. In: Kunath, H., Lochmann, U., Straube, R., Jöckel, K.H., Köhler, C.O. (Hrsg.): Medizinische Informatik, Biometrie und Epidemiologie. , 1995; 475-480.
  • Holländer N, Sauerbrei W: On statistical approaches for the multivariable analysis of prognostic marker studies. In: Jean-Louis Auget, N. Balakrishnan, Mounir Mesbah, Geert Molenberghs (Hrsg.): Advances in Statistical Methods for the Health Sciences. Applications to Cancer and AIDS Studies, Genome, Sequence Analysis, and Survival Analysis., 1. Auflage. Boston: Birkhäuser Boston, 2007; 19-38.
  • Jäger W, Löffler B, Beck E, Wolf A, Mund-Hoym S, Sauerbrei W, Wildt L, Lang N: Retrospective analysis of GnRH analogue administration in patients with advanced ovarian cancer. In: Lunenfeld B (Hrsg.): Advances in the study of GnRH analogues 4. GnRH analogues and cancer. Parthenon Publishing Group, 1992; 69-76.
  • Kommoss F, Pfisterer J, Thome M, Sauerbrei W, Pfleiderer A: Steroid Rezeptoren beim Ovarialkarzinom: Die immunhistochemische Bestimmung birgt neue Perspektiven. In: Meerpohl HG, Pfleiderer A, Profous CZ (Hrsg.): Das Ovarialkarzinom. Berlin - Heiderlberg: Springer, 1993; 119-129 (Bd 1 Tumorbiologie Screening, Staging.).
  • Lang C, Sauerbrei W, Berendes T: Vocational and social reintegration and rehabilitation following infarction in the area of the middle celrebral artery. In: Vakil E, Hofien D, Groswasser Z (Hrsg.): Rahabilitation of the brain injured person: a neuropsychological perspective. London: Freund Publishing House, 1990; 177-188.
  • Lausen B, Sauerbrei W, Schumacher M: Classification and regression trees used for the exploration of prognostic factors measured on different scales. In: Dirschedl, P., Ostermann, R. (Hrsg.): Computational Statistics. Physica-Verlag, Heidelberg, 1994; 483-496.
  • Madjar H, Sauerbrei W, Ladner HA, Pfleiderer A: Sonographic detection of occult tumor extension. In: Madjar H, Teubner J, Hackloer B-J (Hrsg.): Breast Ultrasound Update. Karger, Basel, 1994; 140-146.
  • Madjar H, Sauerbrei W, Mundinger A, Prömpeler H, Pfleiderer A: Color doppler flow assessment of breast disease. In: Madjar H, Teubner J, Hacklöer B-J (Hrsg.): Breast Ultrasound Update. Karger, Basel, 1994; 298-307.
  • Madjar H, Sauerbrei W, Schillinger H: Aktueller Stand der Dopplertechniken. In: Gebhardt J, Hackeloeer BJ, v. Klingräff G, Seitz K (Hrsg.): Ultraschalldiagnostik ´89. Berlin: Springer, 1990; 37-39.
  • Meerpohl HG, Sauerbrei W: Welche Bedeutung hat die Dokumentation in der Nachsorge für die Therapieüberwachung und Therapieplanung bei gynäkologischen Tumoren In: Meerpohl HG, Pfleiderer A, Profus CZ (Hrsg.): Das Rezidiv in der Gynäkologischen Onkologie Berlin - Heidelberg - New York: Springer-Verlag, 1990; 102-113.
  • Pfisterer J, Kommoss F, Renz H, Sauerbrei W, Meerpohl HG, Teufel G, Pfleiderer A: Die flowzytometrische Bestimmung des nukeären DNA-Gehaltes bei malignen epithelialen Tumoren der Ovarien. In: Das Ovarialkarzinom. Berlin - Heidelberg: Springer, 1993; 111-118 (Bd 1 Tumorbiologie, Screening, Staging.).
  • Sauerbrei W: Bedeutung und Evaluierung prognostischer Faktoren. In: Lang N, Jäger W (Hrsg.): Zytoststika-Resistenz. Jena: Universitätsverlag, 1991; 101-110.
  • Sauerbrei W: Comparison of variable selection procedures in regression models - a simulation study and practical examples. In: Michaelis J, Hommel G, Wellek S (Hrsg.): Europäische Perspektiven der Medizinischen Informatik, Biometrie und Epidemiologie. München: Medizin Verlag, 1993; 108-113.
  • Sauerbrei W: On the development and validation of classification schemes in survival data. In: Klar, R, Opitz, O (Hrsg.): Classification and Knowledge Organization Springer-Verlag, 1997; 509-518.
  • Sauerbrei W: Bootstraping in Survival Analysis. In: Armitage, P, Colton T (Hrsg.): Encyclopedia of Biostatistics John Wiley & Sons, 1998; 433-436.
  • Sauerbrei W: Investigations on stability and overoptimsm of classification trees by using cross-validation. In: Crespo Jose, Maojo Victor, Martin Fernando (Hrsg.): Medical Data Analysis: second international symposium; proceedings Berlin: Springer, 2001; 251-257.
  • Sauerbrei W: Prognostic Factors. Confusion caused by bad quality of design, analysis and reporting of many studies. In: Bier H (Hrsg.): Current Research in Head and Neck Cancer. Basel: Karger, 2005; 184-200.
  • Sauerbrei W: Covariates. In: Wiley StatsRef: Statistics Reference Online Wiley StatsRef, 2014.: http://dx.doi.org/10.1002/9781118445112.stat06792
  • Sauerbrei W, Antes G: Investigations on variable selection methods in regression models In: Faulbaum, F (Hrsg.): Softstat '91 - Advances in Statistical Software Stuttgart: Fischer, 1992; 259-266 (3).
  • Sauerbrei W, Blettner M: Issues of Reviews and Meta-Analyses of Observational Studies. In: Ralf Schulze, Heinz Holling, Dankmar Böhning (Hrsg.): Meta-Analysis. New Developments and Applications in Medical and Social Sciences. Göttingen: Hogrefe & Huber, 2003; 79-96.
  • Sauerbrei W, Blettner M, Schumacher M: Basic statistical principles for the evaluation of risk factors. In: Madjar, H., Teubner, J., Hackelöer B-J (Hrsg.): Breast Ultrasound Update. Basel, Karger, 1994; 1-12.
  • Sauerbrei W, Diepgen TL: Statistical aspects of the development and validation of a diagnostic score. In: Kunath, H., Lochmann, U., Straube, R., Jöckel, K.H., Köhler, C.O. (Hrsg.): Medizinische Informatik, Biometrie und Epidemiologie. , 1995; 484-490.
  • Sauerbrei W, Diepgen TL: Use of cross-validation to assess diagnostic classification schemes of atopic dermatitis. In: Klar, R, Opitz, O (Hrsg.): Classification and Knowledge Organization Springer-Verlag, 1997; 519-529.
  • Sauerbrei W, Royston P: Determination of functional relationships for continuous variables by using a multivariable fractional polynomial approach. In: Colosimo A, Guiliani A, Sirabella P (Hrsg.): Medical Data Analysis Berlin: Sprinter, 2002; 53-60.
  • Sauerbrei W, Royston P: Multivariable Fractional Polynomial Models. In: Lovric M (Hrsg.): International Encyclopedia of Statistical Science. Berlin: Springer, 2011; 899-902.
  • Sauerbrei W, Schumacher M: Klinische Studien als wichtiger Bestandtteil medizinischer Forschung: Aspekte der Planung, Durchführung und Auswertung In: Steiner W, Reck R, Dühmke E (Hrsg.): Funktonserhaltende Therapie des frühen Larynxkarzinoms Stuttgart New York: Thieme, 1990; 147-159.
  • Sauerbrei W, Schumacher M: Boostrap and cross-validation to assess complexity of data-driven regression models In: Brause, RW and Hanisch, E (Hrsg.): Medical Data Analysis: first international symposium; proceedings Springer Berlin, 2000; 234-241.
  • Sauerbrei W, Zaiss A, Lausen B, Schumacher M: Evaluierung prognostischer homogener Subpopulationen mit Hilfe der Methode der Klassifikationabäume. In: Guggenmoos-Holzmann I (Hrsg.): Quantitative Methoden in der Epidemiologie. Berlin - Heidelberg - New York: Springer, 1991; 229-234.
  • Schauer A, Marx D, Lipp I, Meden H, Schumacher M, Sauerbrei W, Sauer R, Rauschecker H: Clinical and scientific aspects of HER 2/NEU erb B2-oncogenes: Biological relevance of c-erb B2-oncogene in malignant epithelial tumors. In: Löning J (Hrsg.): Clinical and scientific aspects of HER 2/NEU erb. International Symposium Hamburg 1991. Berlin: Springer, 1992.
  • Schumacher M, Bastert G, Bojar H, Hübner K, Olschewski M, sauerbrei W, Schmoor C, for the German Breast Cancer Study Group (GBSG): A randomized clinical trial evaluating the duration of chemotherapy in patients with primary, node-positive breast cancer. In: Salmon SF (Hrsg.): Adjuvant therapy of cancer VII. Philadelphia: Lippincott, 1993; 193-203.
  • Schumacher M, Holländer N, Schwarzer G, Binder H, Sauerbrei W: Prognostic Factor Studies. In: Crowley J, Hoering A (Hrsg.): Handbook of Statistics in Clinical Oncology, Third Edition. Chapman and Hall/CRC, 2012; 415-470.
  • Schumacher M, Holländer N, Schwarzer G, Sauerbrei W: Prognostic Factor Studies. In: John Crowley (Hrsg.): Handbook of Statistics in Clinical Oncology New York - Basel: Marcel Dekker, Inc., 2001; 321-378.
  • Schumacher M, Holländer N, Schwarzer G, Sauerbrei W: Prognostic Factor Studies. In: John Crowley and Donna Pauler Ankerst (Hrsg.): Handbook of Statistics in Clinical Oncology., 2. Auflage. Boca Raton, FL: Chapman & Hall /CRC, 2006; 289-333.
  • Schumacher M, Sauerbrei W: Statistische Aspekte der Planung, Durchführung und (Meta-) Analyse. In: Meerpohl HG, Pfleiderer A, Profous CZ (Hrsg.): Das Ovarialkarzinom. Bd. 2 Therapie. Berlin - Heidelberg: Springer-Verlag, 1993; 71-85.
  • Steiner W, Iro H, Gewalt K, Sauerbrei W: Ergebnisse der endolaryngeal laser-mikrochirurgisch behandelten Krebsfrühstadien der Glottis. In: Steiner W, Reck R, Duehmke E (Hrsg.): Funktionserhaltende Therapie des frühen Larynxkarzinoms. Stuttgart: Thieme, 1990; 130-140.
  • Steiner W, Iro H, Petsch S, Sauerbrei W: Lasermikrochirurgische Behandlung von Larynkarzinomen (pT 2-4). Darstellung der Langzeitergebnisse. In: Duehmke E, Steiner W, Reck R (Hrsg.): Funktionserhaltende Therapie des fortgeschrittenen Larynkarzinoms. Stuttgart: Thieme, 1991; 80-91.
  • Steiner W, Stenglein C, von Glass W, Sauerbrei W: Ergebnisse mit der funktionserhaltenden lasermikrichirurgischen Tumorresektion beim Hypopharynxkarzinom als Alternative zu Laryngektomie. In: Fleischer K, Ey W (Hrsg.): Verhandlungsbericht der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie. Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie, 1990; 222-223 (Supplement II).
  • Taghavy A, Bohmann G, Sauerbrei W: Zur Vermeidbarkeit der Fehldiagnose MS - der Beitrag der Klinischen Untersuchung. In: Firnhaber W, Dworschak K, Lauer K, Nichtweiß M (Hrsg.): Verhandlungen der Deutschen Gesellschaft für Neurologie. Berlin: Springer, 1991; 85-86.
Editions (miscellany):
  • Meerpohl HG, Sauerbrei W, Schumacher M, Pfleiderer A (Hrsg.): Welche Parameter beeinflussen die Größe des postoperativen Tumorrestes beim fortgeschrittenen Ovarialkarzinom?, Berlin: Springer-Verlag, 1990 (Berichte Gynäkologie Geburtshilfe 127).
Short Communications:
  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Re: Reporting recommendations for tumor marker prognostic studies (REMARK), Response of Authors. J Natl Cancer I, 2005; 97: 1855-1856.
  • Royston P, Sauerbrei W, Altman DG: Modelling the effects of continuous risk factors. Letter to the Editors J Clin Epidemiol, 2000; 53: 219-222.
  • Sauerbrei W, Royston P: Exaggeration of the prognostic effect of mammostrat: A consequence of poor reporting? J Clin Oncol, 2013; 31: 2760-2761. : http://dx.doi.org/10.1200/JCO.2013.49.2652
  • Sauerbrei W, Royston P, Schumacher M: Austin, P.C., and Tu, J.V. (2004), "Bootstrap Methods for developing predictive models", The American Statistician,58, 131-137: Comment by Sauerbrei, Royston, and Schumacher to reply. Am Stat, 2005; 59: 116-118.
  • Sauerbrei W, Royston P, Schumacher M: Comments on ‘Performance of using multiple stepwise algorithms for variable selection’ by Ryan E. Wiegand, Statistics in Medicine 2010; 29:1647–1659. Stat Med, 2011; 30: 892-894. : http://dx.doi.org/10.1002/sim.4083
Other publications (type Sonstiges):
  • Kasenda B, Sauerbrei W, Royston P, Briel M: Investigation of continuous effect modifiers of higheror lower PEEP in mechanically ventilated patients with acute lung injury or ARDS – ICEMstudy. 2012. : http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012003129
  • Royston P, Sauerbrei W: Interactions between treatment and continuous covariates: A step toward individualizing therapy. J Clin Oncol, 2008; 26: 1397-1399.